EPISODE · Jan 17, 2025 · 13 MIN
A “Game Changer” For The High-Risk MDS Patient Population
from Citeline Podcasts · host Norstella
Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions. In Vivo questions the current progress of their lead asset BEXMAB and its potential moving forward.
What this episode covers
Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions. In Vivo questions the current progress of their lead asset BEXMAB and its potential moving forward.
NOW PLAYING
A “Game Changer” For The High-Risk MDS Patient Population
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m